drugset / Trial / NCT05928585

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

NCT05928585 ↗

Phase 1 Completed 30 enrolled HI-Bio, A Biogen Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The goal of this clinical trial is to test safety of the investigational product in healthy volunteers. The main questions it aims to answer is when HIB210 is administered as multiple doses, is it: 1. Safe 2. Well tolerated 3. Does the body absorb and eliminate HIB210 as expected

Timeline

Start
2023-07-06
Primary completion
2024-06-10
Completion
2024-06-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HIB210 Monoclonal antibody — —